UGT1A1 testimine võib tuvastada irinotekaani aktiivse metaboliidi vähenenud kliirensi ja aidata määrata ohutuma algannuse. See ei suuda ennustada kõiki reaktsioone ning otsus sõltub täpsest ravimvormist, raviskeemist ja teie onkoloogiameeskonna hinnangust.
Peamised järeldused
- UGT1A1 testimine tuvastab pärilikud erinevused SN-38 inaktiveerimises; rutiinsed bilirubiini- või maksaanalüüsid ei saa geneetilist tulemust asendada.
- Aeglased metaboliseerijad on tavaliselt genotüübiga *28/*28, *6/*6 või *6/*28, millega kaasneb irinotekaaniga seotud raske neutropeenia suurem risk.
- Keskmise aktiivsusega metaboliseerijad on tavaliselt genotüübiga *1/*28 või *1/*6; Hollandi farmakogeneetika töörühm ei soovita nende patsientide puhul automaatset üksnes genotüübil põhinevat annuse vähendamist.
- Algannuse soovitus on erinev: Hollandi ravijuhend soovitab aeglastele metaboliseerijatele 70% tavalisest irinotekaani algannusest, millele järgneb arsti juhitud annuse kohandamine.
- Raviskeem on oluline, sest tavapärase FOLFIRI korral kasutatakse sageli 180 mg/m² iga 2 nädala järel, samas kui teiste manustamisskeemide ja liposomaalsete ravimvormide annused on erinevad.
- Liposomaalne irinotekaan on ravimvormipõhised juhised; 70 mg/m² raviskeemi ja 50 mg/m² raviskeemi ei tohi käsitada vastastikku asendatavatena.
- Hiline kõhulahtisus algab rohkem kui 24 tundi pärast irinotekaani manustamist ning võib vedelikupuuduse, elektrolüütide kao või kaasneva neutropeenia tõttu muutuda ohtlikuks.
- Kiireloomuline hindamine on vajalik keemiaravi ajal kehatemperatuuri korral 38.0°C või kõrgem, välja arvatud juhul, kui teie onkoloogiameeskond on määranud teistsuguse, rangema piirmäära.
Mida muudab UGT1A1 test enne esimest infusiooni?
A UGT1A1 test enne irinotekaani tuvastab vähenenud võime inaktiveerida SN-38, ravimi aktiivset metaboliiti. Tulemused, näiteks 28/*28, *6/*6 või *6/*28 võivad toetada väiksema algannuse kasutamist ning neutropeenia ja hilise kõhulahtisuse hoolikamat jälgimist; onkoloogiameeskond peab tulemuse siduma tegeliku raviskeemiga.
Testimisest on kõige rohkem kasu enne 1. ravitsüklit, sest pärilik erinevus ravimi kliirensis esineb juba enne raviga seotud sümptomite tekkimist. Tulemus ei mõõda, kui palju irinotekaani praegu organismis ringleb, ega näita, kas keemiaravi toimib; neile küsimustele vastatakse ravi käigus jälgitava ravivastuse, kliinilise hindamise ja vahel spetsialisti farmakokineetiliste meetoditega.
Hüpoteetiline patsient, kellele on kavandatud tavapärane irinotekaan annuses 180 mg/m², võib pärast aeglase metaboliseerija tulemust saada teistsuguse algannuse plaani, samal ajal kui mõni teine sama genotüübiga patsient võib juba saada väiksema annusega kombinatsioonravi. Kasulik küsimus ei ole lihtsalt see, kas tulemus on positiivne: küsige, millist algannust, jälgimisgraafikut ja annuse suurendamise kriteeriume tulemus muudab.
Kantesti on AI vereanalüüsi analüsaator mis aitab selgitada tavapäraseid CBC ja bilirubiini analüüside vastuseid, mitte laborit, mis teeb UGT1A1 genotüpiseerimist, ega teenust, mis määrab keemiaravi. Meie organisatsioon ja kliiniline eesmärk erinevad teie onkoloogiameeskonna ravimi määramise rollist; hoidke geneetilist raportit ja ravitsüklipõhiseid laboritulemusi ravikirjes eraldi.
Kuidas mõjutavad UGT1A1 *28 ja *6 irinotekaani metabolismi?
UGT1A1 *28 vähendab ensüümi ekspressiooni, samas kui UGT1A1 *6 variant vähendab kodeeriva muutuse kaudu ensüümi funktsiooni. Mõlemad võivad aeglustada aktiivse SN-38 muundamist palju vähem aktiivseks glükuroniidiks SN-38G; see suurendab ekspositsiooni, ilma et ALT või AST tulemused peaksid olema ebanormaalsed.
Karboksüülesteraasid muundavad irinotekaani esmalt SN-38-ks; seejärel osaleb UGT1A1 SN-38 inaktiveerimises, mitte selle esialgses aktiveerimises. *28 alleel sisaldab tavaliselt 7 promootori TA-kordust, mitte *1-ga seotud 6 kordust, samas kui *6 kirjeldatakse tavaliselt kujul c.211G>A, mis põhjustab p.Gly71Arg asenduse.
Sama ensüüm konjugeerib ka bilirubiini, mis selgitab seost Gilberti sündroomi ja bilirubiiniga. Normaalne bilirubiinitulemus ei välista siiski vähenenud funktsiooniga genotüüpi ning suurenenud tulemus ei näita, milline variant esineb; paastumine, haigus, obstruktsioon ja maksafunktsiooni kahjustus võivad muuta ühe mõõtmise tõlgendust.
Minami jt uurisid Jaapani patsientidel nii *6 kui ka *28 varianti ning seostasid UGT1A varieeruvuse irinotekaani farmakokineetika ja toksilisusega (Pharmacogenetics and Genomics, 2007). Nende töö on oluline, sest ainult *28 varianti hõlmav test võib jätta märkamata kliiniliselt olulise *6 alleeli; 2 patsienti, keda kirjeldatakse kui *28-negatiivseid, ei pruugi SN-38 kliirensi poolest samasugused olla.
Millised tulemused tähendavad, et UGT1A1 metaboliseerija on aeglane?
A UGT1A1 aeglane metaboliseerija generally carries 2 decreased-function alleles, including 28/*28, *6/*6 või *6/*28. A person with *1/*28 or *1/*6 usually has an intermediate-metabolizer phenotype; *1/*1 is usually classified as normal when the test adequately covers relevant variants.
The slash separates the 2 inherited gene copies; it is not a fraction or a drug concentration. A *6/*28 result usually means one decreased-function allele came from each parent, creating a compound-heterozygous poor-metabolizer result; possessing 2 different allele names does not make the result less clinically relevant than *28/*28.
Intermediate metabolism is not the same as zero risk. Although the Dutch guideline does not recommend an automatic reduction for *1/*28 or *1/*6, a patient starting at 180 mg/m² may still need modification because of elevated bilirubin, limited marrow reserve, previous toxicity, or the accompanying drugs; the phenotype is one input, not permission to ignore the rest.
Pharmacogenetic recommendations are drug-specific, as our explanation of SLCO1B1-related medication risk also illustrates. A reduced-function result does not mean every medicine is unsafe, and *28/*28 does not itself diagnose a hereditary cancer syndrome; ask the laboratory to provide the diplotype, assigned phenotype, and variants tested rather than a 1-word positive result.
Mida peaks geneetiline test hõlmama ja millal seda vaja on?
The test should clearly state whether it detects both *28 and *6, how it assigns the 2 alleles, and which other variants it evaluates. Testing before the first irinotecan dose allows the result to influence prevention rather than merely explain toxicity after it occurs.
UGT1A1 *6 is more frequent in several East Asian populations, while *28 occurs across multiple ancestry groups; ancestry can inform test coverage but cannot substitute for testing. Some assays also distinguish the 5-repeat *36 and 8-repeat *37 alleles, so reports from 2 laboratories may differ because their analytical scope differs—not because your inherited genotype changed.
A laboratory may use a blood-derived DNA sample or a validated saliva or cheek-cell method; fasting is not ordinarily required for the genetic analysis itself. Recent allogeneic stem-cell transplantation needs special discussion because circulating DNA may reflect the donor, and turnaround time must be checked locally rather than assumed to fit a treatment appointment in 2 days.
Genotyping and enzyme-activity testing are not interchangeable, a distinction also relevant to TPMT test interpretation. UGT1A1 genotype generally needs testing only once, but a narrow panel may warrant additional analysis if the clinical picture is unexpected; a report listing only 1 tested variant should not be read as proof that every other reduced-function allele is absent.
Kui palju suurendab UGT1A1 raske neutropeenia riski?
Poor-metabolizer genotypes increase the likelihood of raske neutropeenia, but the size of the increase depends on dose and regimen. Grade 3 neutropenia generally means an absolute neutrophil count below 1.0 down to 0.5 × 10⁹/L; grade 4 means below 0.5 × 10⁹/L.
Hoskins et al. reported a dose-dependent association between *28/*28 and irinotecan-related neutropenia in their 2007 Journal of the National Cancer Institute meta-analysis. In the 150–250 mg/m² category, the pooled odds ratio was 3.22, with a 95% confidence interval of 1.52–6.81; older mixed schedules and wide uncertainty prevent treating this as a personal probability.
An odds ratio is not the percentage of patients affected. In a purely hypothetical illustration, if baseline risk were 10%, an odds ratio of 3 would correspond to approximately 25% risk—not 30%; the actual baseline varies with companion drugs, supportive care, prior treatment, and eligibility criteria, so no single percentage applies to every poor metabolizer.
Kantesti can help readers distinguish the ANC from the neutrophil percentage in routine reports, using the concepts explained in our absoluutse neutrofiilide arvu juhend. A pre-existing Duffy-null-associated lower ANC requires individualized interpretation, but a new chemotherapy-related fall below 0.5 × 10⁹/L still deserves prompt oncology assessment rather than reassurance based on ancestry alone.
Miks erinevad irinotekaani manustamise ajal tekkiv ja hilinenud kõhulahtisus?
Early diarrhea occurs during or shortly after infusion, usually within 24 hours, and may accompany cholinergic symptoms such as sweating or abdominal cramping. Hiline kõhulahtisus begins more than 24 hours after treatment and is more closely related to intestinal toxicity, including exposure to SN-38.
UGT1A1 genotype is more useful for anticipating delayed toxicity than predicting the immediate cholinergic syndrome. Clinicians may use atropine for early symptoms when appropriate, while delayed diarrhea requires a separate written treatment plan; intestinal bacteria can convert SN-38G back to SN-38 through beta-glucuronidase activity, illustrating why liver conjugation is not the only determinant of bowel exposure.
Grade 3 diarrhea commonly includes at least 7 additional stools per day above baseline, hospitalization being indicated, or a severe increase in ostomy output. Do not wait to reach that count before calling: persistent diarrhea despite the prescribed plan, vomiting that prevents drinking, fever, dizziness, or reduced urine output can justify urgent assessment at a much smaller stool increase.
Diarrhea during chemotherapy should not automatically be attributed to genotype, because antibiotics, infections, and accompanying drugs can produce similar symptoms; our C. difficile result guide explains one relevant diagnostic complication. If diarrhea lasts beyond 24 hours despite your oncology instructions, contact the team, and treat blood in the stool or significant abdominal pain as warning signs rather than ordinary treatment effects.
Kuidas mõjutab raviskeem algannuse määramise otsust?
A starting-dose decision combines UGT1A1 phenotype with the planned regimen, not genotype alone. Conventional FOLFIRI commonly uses irinotecan 180 mg/m² every 2 weeks, whereas modified combinations may use 150 mg/m² or another protocol-specific amount; those differences change baseline exposure and toxicity.
The Dutch Pharmacogenetics Working Group recommends starting poor metabolizers at 70% of the normal irinotecan dose, with subsequent increases guided by neutrophil counts and clinical tolerance (Hulshof et al., 2023). Applied hypothetically to a 180 mg/m² protocol, 70% is 126 mg/m²; the prescribing team decides whether protocol rules permit rounding, what dose level to use, and when reassessment occurs.
A 70% calculation is relative to the regimen’s usual starting dose, not a fixed universal dose. For a hypothetical protocol starting at 150 mg/m², the same calculation gives 105 mg/m²; applying the 126 mg/m² figure from a different protocol would therefore be a genuine dosing error, especially if the infusion schedule or formulation also differed.
Kantesti on AI vereanalüüsi tulemuste tõlgendamise platvorm for explaining reported laboratory values, not selecting a 180 mg/m² chemotherapy prescription; our kliinilise valideerimise raamistikku describes the distinction between interpretation support and prescribing. In combinations containing fluorouracil or capecitabine, DPYD testimine enne keemiaravi addresses a separate metabolic risk that a normal UGT1A1 result cannot rule out.
Miks erinevad irinotekaani annustamissoovitused juhendite lõikes?
Guidelines differ because they interpret dose-dependent evidence differently and serve different clinical settings. The Dutch guideline recommends a 70% starting dose for poor metabolizers, while US conventional irinotecan prescribing information advises considering a reduction by at least 1 dose level, without defining one percentage for every regimen.
A dose level is defined by the treatment protocol rather than by the genetic test. Moving from 180 to 150 mg/m² would be approximately a 17% reduction, while moving from 180 to 120 mg/m² would be approximately a 33% reduction; these are mathematical examples, not recommendations, and explain why the phrase reduce one level needs a named protocol.
The French RNPGx/GPCO dose-stratified framework has historically distinguished doses below 180 mg/m², doses of 180–230 mg/m², and high doses of at least 240 mg/m². It recommended approximately 25–30% reduction for *28/*28 at the intermediate range and advised against high-dose use in that genotype; the Dutch recommendation is broader, including lower-dose regimens and other poor-metabolizer combinations.
The evidence is genuinely less settled at lower doses, where severe events may be less frequent and studies less able to estimate genotype effects precisely. This differs from HLA-B*57:01 drug avoidance, where the relevant recommendation is avoidance rather than a 30% reduction; ask which local guideline your team follows and whether its advice specifically covers *6/*6 or *6/*28.
Kas liposomaalse irinotekaani puhul kehtivad samad UGT1A1 annustamisreeglid?
Liposomal irinotecan is not interchangeable with conventional irinotecan, and its UGT1A1 instructions depend on the regimen. In the liposomal irinotecan plus fluorouracil/leucovorin setting, a usual 70 mg/m² dose is reduced to 50 mg/m² initially for known *28/*28; the NALIRIFOX regimen already starts at 50 mg/m².
Those 70 and 50 mg/m² figures refer to irinotecan free base in the relevant liposomal prescribing instructions. Some documents also express doses using the hydrochloride trihydrate equivalent, approximately 80 and 60 mg/m² respectively; the team must verify the convention rather than interpret a different-looking number as an intentional dose increase or decrease.
For NALIRIFOX—liposomal irinotecan with oxaliplatin, fluorouracil, and leucovorin—the labeled starting dose is 50 mg/m² every 2 weeks, including patients known to have *28/*28. This does not establish that every poor-metabolizer genotype has identical evidence, especially *6-containing combinations; the oncology pharmacist should check the relevant product information and local protocol rather than import conventional irinotecan rules automatically.
A medication list that says only irinotecan is insufficient for a pharmacogenetic decision: request the formulation, companion drugs, dose expression, and schedule before comparing 2 plans. Our laboratoorseteks alganalüüsideks valmistumise juhendi also explains why recording pretreatment measurements helps later interpretation, although those measurements cannot resolve a formulation or prescribing ambiguity.
Millised laboratoorsete analüüside tulemused ja ravimid on koos genotüübiga olulised?
CBC with differential, bilirubin, liver tests, kidney function, and electrolytes provide information that UGT1A1 genotype cannot supply. A bilirubin of 2.0 mg/dL is approximately 34 µmol/L; conventional irinotecan studies often excluded values above this level, so higher results require specialist assessment rather than a genotype-only calculation.
An isolated indirect bilirubin rise may fit reduced UGT1A1 activity, while rising direct bilirubin with abnormal ALP or transaminases suggests an additional hepatobiliary problem. A hypothetical total bilirubin of 1.8 mg/dL with otherwise stable tests is therefore not equivalent to 1.8 mg/dL accompanied by new jaundice and obstruction; fractionation, trends, symptoms, and imaging determine the interpretation.
Strong CYP3A4 inducers can lower irinotecan exposure, while strong CYP3A4 or UGT1A1 inhibitors can increase clinically relevant exposure; examples requiring pharmacy review include rifampicin, carbamazepine, ketoconazole, and atazanavir. Do not stop a prescription yourself, and disclose supplements such as St John’s wort before cycle 1 because changing an interacting medicine can itself change exposure.
Kantesti can help explain routine kidney and electrolyte reports, but a normal creatinine does not guarantee tolerance of delayed diarrhea. The BUN/ kreatiniini suhte juhendist describes contextual interpretation, while our electrolyte safety guide explains why potassium or magnesium losses can matter after 24 hours of gastrointestinal symptoms.
Milline jälgimine ja millised sümptomid nõuavad kiiret tegutsemist?
Monitoring remains necessary for every genotype, with CBC checks before treatment and additional measurements when clinically indicated. A temperature of 38.0°C või kõrgem during chemotherapy warrants immediate contact with the oncology service unless the team has supplied a different threshold; follow a stricter local instruction.
Formal definitions of febrile neutropenia often use a single temperature of 38.3°C or a temperature of 38.0°C sustained for 1 hour, together with a low or falling ANC. These definitions are not instructions to wait at home: chemotherapy services often use simpler, more cautious telephone thresholds, and shaking chills, confusion, or sudden deterioration can be urgent without a documented fever.
A falling ANC can precede symptoms, so a patient feeling well should still attend the scheduled laboratory check. Our borderline neutrophil interpretation guide explains why a result near a cutoff needs context; during treatment, a change from 2.5 to 0.7 × 10⁹/L carries different significance from a stable longstanding count near 1.4 × 10⁹/L.
Dose escalation after a reduced start should follow a predefined plan based on counts, diarrhea, other toxicity, and treatment goals—not simply the absence of nausea after cycle 1. G-CSF may reduce neutropenia risk when indicated, but it does not prevent intestinal toxicity; urgent assessment is needed for diarrhea with fever, severe abdominal pain, inability to drink, or markedly reduced urination.
Miks võivad rasked kõrvaltoimed tekkida ka normaalse genotüübi korral?
A normal UGT1A1 result does not guarantee safe treatment because irinotecan toxicity has multiple causes. Genotype does not adequately predict every episode of nausea, fatigue, hair loss, infusion symptoms, or toxicity from companion drugs; even *1/*1 patients can develop severe neutropenia or diarrhea.
A narrow assay may miss uncommon reduced-function variants, while liver impairment, interacting medicines, treatment intensity, and previous chemotherapy can increase risk independently. Thus, 2 patients both reported as *1/*1 may have different exposures and different marrow reserve; a phenotype assignment only describes the genetic information captured by the test, not every biological factor affecting treatment.
Companion drugs create additional attribution problems: oxaliplatin can cause neuropathy, and fluoropyrimidines can contribute diarrhea, mucositis, and marrow suppression. A hypothetical patient on a 4-drug combination with severe diarrhea cannot have the culprit assigned from UGT1A1 alone; timing, the complete regimen, microbiological testing when indicated, and other pharmacogenetic results may alter the clinical explanation.
Kantesti’s role in laboratory trend interpretation is to support understanding, not establish which drug caused a change between 2 cycles. Genetic reports also contain durable personal information, so review our privaatsus- ja andmetöötluspõhimõtetega before sharing them; an inherited metabolic variant is not a complete forecast of your future health.
Mida peaksite enne irinotekaani saamist oma onkoloogiameeskonnalt küsima?
Before treatment, ask which formulation and regimen you will receive, whether *28 and *6 were tested, and how the result changes the first dose. Also obtain a written diarrhea plan, a temperature threshold, and a 24-hour contact route; these practical details matter even when the genotype is normal.
Request the actual dose in mg/m² and the planned total dose in mg, because they answer different questions. For example, a hypothetical 126 mg/m² order for a body surface area of 1.8 m² gives 226.8 mg before institutional rounding; patients should not perform their own adjustment, but this distinction helps identify whether 2 documents describe the same prescription.
Ask how the team will judge tolerance after cycle 1, whether an interim CBC is planned, and what would justify later escalation. Your written diarrhea instructions may use a loperamide schedule different from ordinary over-the-counter directions, so follow the oncology prescription rather than inventing a schedule; fever, abdominal pain, or persistent symptoms may require assessment instead of additional self-treatment.
Kantesti on AI-põhine vereanalüüsi analüüsitööriist that can help explain routine reports alongside your own treatment notes; our AI-tehnoloogia juhend explains the supporting technology rather than a chemotherapy dosing system. Keep 3 items accessible: the genetic report, the current regimen sheet, and the emergency contact instructions, with the prescribing team verifying all clinical decisions.
Teaduspublikatsioonid: mis toetab soovitusi ja mis mitte?
The dosing advice rests on drug-specific pharmacogenetic guidance and irinotecan studies, not on general blood-test education publications. The 2023 Dutch guideline recommends a 70% start for poor metabolizers, while the 2007 studies cited here help explain dose dependence and the relevance of both *28 and *6.
Hulshof et al. translate pharmacokinetic and toxicity evidence into prescribing guidance, whereas Hoskins et al. quantify associations across older dose categories, and Minami et al. examine relevant variants in Japanese patients. These 3 sources answer complementary questions; none supplies an individualized toxicity percentage for every contemporary combination, and observational associations should not be presented as proof that one starting dose suits everyone.
Kantesti’s 2 Zenodo publications listed below are educational resources on RDW and the BUN/creatinine ratio, not trials of UGT1A1-guided irinotecan dosing. Our RDW and CBC interpretation resource can explain accompanying red-cell indices, but RDW does not replace ANC, genotype, or a chemotherapy protocol; a DOI is a persistent identifier, not an automatic guarantee of clinical relevance or peer review.
The unresolved question is often how best to preserve treatment intensity while preventing a severe event in cycle 1, particularly in lower-dose combinations and less-studied genotypes. Our meditsiinilise sisu standardid require separating established guidance, hypothetical calculations, and genuine uncertainty; the oncology team should confirm the current local product information and protocol before applying any published recommendation.
Korduma kippuvad küsimused
Kas kõigile tuleks enne irinotekaani manustamist teha UGT1A1 test?
Testimispoliitika erineb riigiti, asutuseti ja raviskeemiti, kuid Hollandi farmakogeneetika töörühm soovitab enne irinotekaanravi teha UGT1A1 testi. Tulemus on eriti kasulik enne esimest ravitsüklit, sest selle abil saab halvad metaboliseerijad tuvastada enne raske toksilisuse tekkimist. Test peaks selgitama, kas see hõlmab nii *28 kui ka *6 varianti, mitte piirduma üksnes teatega, et *28 puudub. Teie onkoloogiameeskond peaks selgitama, kas testitulemus muudab teie konkreetset algannust ja kas tulemuse ootamine on asjakohane.
Mida tähendab UGT1A1 *28/*28 irinotekaani annustamise seisukohalt?
UGT1A1 *28/*28 viitab üldjuhul aeglasele metaboliseerimisele ja irinotekaaniga seotud raske neutropeenia suurenenud riskile. Hollandi ravijuhend soovitab 70% tavalisest algannusest, millele järgneb arsti juhitud kohandamine taluvuse ja neutrofiilide arvu järgi. Hüpoteetilise tavapärase 180 mg/m² raviskeemi puhul on arvutustulemus 126 mg/m² enne raviprotokollist sõltuvate otsuste tegemist või ümardamist. USA ravimi väljakirjutamise juhised ja liposomaalsed raviskeemid kasutavad teistsuguseid lähenemisviise, seega ei ole see arvutus isiklik ravimiannuse määrang.
Kas UGT1A1 *6 on enne irinotekaani kasutamist sama oluline kui *28?
UGT1A1 *6 on kliiniliselt oluline vähenenud funktsiooniga variant, mis võib vähendada SN-38 inaktiveerimist. Tulemused nagu *6/*6 või *6/*28 viitavad üldjuhul aeglase metaboliseerija staatusele, sest need sisaldavad 2 vähenenud funktsiooniga alleeli. Variant on mitmes Ida-Aasia populatsioonis sagedasem, kuid üksnes päritolu põhjal ei saa kindlaks teha, kas inimene seda kannab. Enne kui tõlgendate *28-negatiivset tulemust normaalse metabolismina, küsige, kas teie labor uuris *6 varianti.
Kas UGT1A1 *1/*28 korral on annuse automaatne vähendamine vajalik?
UGT1A1 *1/*28 viitab üldjuhul keskmise metaboliseerimisvõimega, mitte aeglase metaboliseerimisvõimega fenotüübile. Hollandi ravijuhend ei soovita keskmise metaboliseerimisvõimega patsientidel annuse algset vähendamist üksnes genotüübi alusel. Patsiendile, kellele on kavandatud annus 180 mg/m², võib siiski olla vaja teistsugust raviplaani bilirubiinitaseme, varasema ravi, koostoimeid põhjustavate ravimite või kombinatsioonraviskeemi tõttu. Keskmine metaboliseerimisvõime ei välista CBC jälgimise ega kõhulahtisuse ohutuskava vajadust.
Kas normaalne bilirubiinitase võib asendada UGT1A1 geneetilist testimist?
Normaalne bilirubiinitase ei välista vähenenud funktsiooniga UGT1A1 genotüüpi ning kõrgenenud bilirubiinitase ei võimalda kindlat alleeli tuvastada. Bilirubiinitase peegeldab mitut protsessi, sealhulgas konjugatsiooni, maksafunktsiooni, obstruktsiooni ja punaliblede käivet. Üldbilirubiini tase 2,0 mg/dl vastab ligikaudu 34 µmol/l ning seda tuleb tõlgendada asjakohase irinotekaani raviprotokolli raames. Geneetiline testimine ja bilirubiini mõõtmine annavad teineteist täiendavat teavet, mitte vahetatavaid vastuseid.
Millal peaksin helistama kõhulahtisuse või palaviku korral pärast irinotekaani?
Kui keemiaravi ajal tõuseb kehatemperatuur 38,0 °C-ni või kõrgemale, võtke kohe ühendust oma onkoloogiateenistusega, välja arvatud juhul, kui ravimeeskond on andnud teistsuguse piirväärtuse, ning järgige kõiki rangemaid juhiseid. Hilinenud irinotekaaniga seotud kõhulahtisus algab rohkem kui 24 tundi pärast ravi ning võib põhjustada vedelikupuudust või elektrolüütide kadu. Helistage viivitamata, kui kõhulahtisus püsib hoolimata teile määratud tegevuskava järgimisest, te ei suuda juua, urineerite tavapärasest vähem, väljaheites on verd või teil on märkimisväärne kõhuvalu. Ärge oodake abi otsimisega, kuni teil on ööpäevas 7 lisakorda roojamist või toimub plaaniline vereanalüüs.
Saage teada, kuidas lugeda vereanalüüsi tulemusi
Laadige oma laboriaruanne üles ja Kantesti AI selgitab iga biomarkerit sekunditega lihtsas keeles. Kasutusel enam kui 2 miljoni inimese seas kogu maailmas.
Viited
- Klein, T., Mitchell, S., & Weber, H. (2026). RDW vereanalüüs: põhjalik juhend RDW-CV, MCV ja MCHC kohta. Kantesti AI meditsiiniuuringud. DOI
- Klein, T., Mitchell, S., & Weber, H. (2026). BUN/Creatinine suhe Selgitatud: Nõrga funktsiooni testijuhend. Kantesti AI meditsiiniuuringud. DOI
- Hulshof DP et al. (2023). Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan. European Journal of Human Genetics.
- Hoskins JM et al. (2007). UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. Journal of the National Cancer Institute. DOI
- Minami H et al. (2007). Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenetics and Genomics.
- 2+ kuudAnalüüsitud testid
- 127+Riigid
- 100+Keeled
Meditsiinimeeskonnast
E-E-A-T usaldussignaalid
Kogemus
Arsti juhitud kliiniline ülevaade labori tõlgendamise töövoogudest.
Ekspertiis
Laborimeditsiin keskendub sellele, kuidas biomarkerid käituvad kliinilises kontekstis.
Autoriteetsus
Meditsiiniliselt retsenseerinud dr Thomas Klein, kaastöölised dr Sarah Mitchell ja prof dr Hans Weber.
Usaldusväärsus
Tõenduspõhine tõlgendus selgete edasiste sammudega, et vähendada ärevust.
Meditsiiniline lahtiütlus
Käesolev artikkel on mõeldud üksnes hariduslikel eesmärkidel ega kujuta endast meditsiinilist nõuannet. Diagnoosi ja ravivalikute otsuste tegemiseks konsulteeri alati kvalifitseeritud tervishoiutöötajaga.
Avaldatud · Võtke ühendust toimetusega
Avaldanud Kantesti Ltd, registreeritud Inglismaal ja Walesis, ettevõtte nr. 17090423, London, Ühendkuningriik.
